4,790 Shares in Illumina, Inc. $ILMN Acquired by Alps Advisors Inc.

Alps Advisors Inc. bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,790 shares of the life sciences company’s stock, valued at approximately $455,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Parkside Financial Bank & Trust increased its holdings in shares of Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares during the last quarter. Quent Capital LLC bought a new stake in shares of Illumina during the 3rd quarter worth $29,000. Cullen Frost Bankers Inc. purchased a new position in Illumina in the second quarter worth $41,000. NewSquare Capital LLC grew its position in Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares in the last quarter. Finally, Mather Group LLC. bought a new position in Illumina in the third quarter valued at $46,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of Illumina stock opened at $116.81 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53. The business’s 50 day simple moving average is $137.29 and its two-hundred day simple moving average is $116.52. The stock has a market capitalization of $17.85 billion, a P/E ratio of 21.43, a price-to-earnings-growth ratio of 2.19 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the firm posted $0.95 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Piper Sandler dropped their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday. Barclays raised their price objective on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. TD Cowen reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Finally, UBS Group reissued a “neutral” rating and set a $135.00 price target on shares of Illumina in a research note on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $129.17.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is owned by insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.